Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 28:2022:8150444.
doi: 10.1155/2022/8150444. eCollection 2022.

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Haiying Liu  1 , Zhengyan Wang  2 , Lijun Ren  3 , Guiqin Zhang  1 , Dan Zhao  4 , Yanli Guo  5 , Lijuan Wang  6 , Hong Feng  7
Affiliations

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Haiying Liu et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Objective: To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS).

Methods: A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group).

Results: Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment.

Conclusion: Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of APACHE II scores and Murray lung injury scores between the two groups of patients. Note: ∗∗∗P < 0.001.
Figure 2
Figure 2
Comparison of SVR, PVR, MAPA, and PAWP between the two groups of patients. Note: ∗∗P < 0.01; ∗∗∗P < 0.001.
Figure 3
Figure 3
Comparison of the serum levels of IL-10, TNF-α, and PCT between the two groups of patients. Note: ∗∗P < 0.01; ∗∗∗P < 0.001.
Figure 4
Figure 4
Comparison of the survival curve between the two groups of patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nanchal R. S., Truwit J. D. Recent advances in understanding and treating acute respiratory distress syndrome. F1000Research . 2018;7:p. 1322. doi: 10.12688/f1000research.15493.1. - DOI - PMC - PubMed
    1. Yadav H., Thompson B. T., Gajic O. Fifty years of research in ARDS. is acute respiratory distress syndrome a preventable disease? American Journal of Respiratory and Critical Care Medicine . 2017;195(6):725–736. doi: 10.1164/rccm.201609-1767CI. - DOI - PubMed
    1. Cardinal-Fernández P., Correger E., Villanueva J., Rios F. Distrés respiratorio agudo: del síndrome a la enfermedad. Medicina Intensiva . 2016;40(3):169–175. doi: 10.1016/j.medin.2015.11.006. - DOI - PubMed
    1. Chacko B., Peter J. V., Tharyan P., John G., Jeyaseelan L. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) Cochrane Database of Systematic Reviews . 2015;1(1) doi: 10.1002/14651858.cd008807.pub2.CD008807 - DOI - PMC - PubMed
    1. Hussain M., Xu C., Ahmad M., et al. Acute respiratory distress syndrome: bench-to-bedside approaches to improve drug development. Clinical Pharmacology and Therapeutics . 2018;104(3):484–494. doi: 10.1002/cpt.1034. - DOI - PMC - PubMed

Publication types